These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 20040696)

  • 1. Lofexidine, an {alpha}2-receptor agonist for opioid detoxification.
    Gish EC; Miller JL; Honey BL; Johnson PN
    Ann Pharmacother; 2010 Feb; 44(2):343-51. PubMed ID: 20040696
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alpha2-receptor agonists for treatment and prevention of iatrogenic opioid abstinence syndrome in critically ill patients.
    Honey BL; Benefield RJ; Miller JL; Johnson PN
    Ann Pharmacother; 2009 Sep; 43(9):1506-11. PubMed ID: 19690220
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Opioid antagonists with minimal sedation for opioid withdrawal.
    Gowing L; Ali R; White JM
    Cochrane Database Syst Rev; 2017 May; 5(5):CD002021. PubMed ID: 28553701
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In-patient detoxification procedures, treatment retention, and post-treatment opiate use: comparison of lofexidine + naloxone, lofexidine + placebo, and methadone.
    McCambridge J; Gossop M; Beswick T; Best D; Bearn J; Rees S; Strang J
    Drug Alcohol Depend; 2007 Apr; 88(1):91-5. PubMed ID: 17064857
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Double-blind study of lofexidine and clonidine in the detoxification of opiate addicts in hospital.
    Kahn A; Mumford JP; Rogers GA; Beckford H
    Drug Alcohol Depend; 1997 Jan; 44(1):57-61. PubMed ID: 9031821
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Opiate withdrawal using lofexidine, a clonidine analogue with fewer side effects.
    Washton AM; Resnick RB; Geyer G
    J Clin Psychiatry; 1983 Sep; 44(9):335-7. PubMed ID: 6355070
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lofexidine for opiate detoxification: review of recent randomised and open controlled trials.
    Strang J; Bearn J; Gossop M
    Am J Addict; 1999; 8(4):337-48. PubMed ID: 10598217
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lofexidine versus clonidine for mitigation of opioid withdrawal symptoms: A systematic review.
    Kuszmaul AK; Palmer EC; Frederick EK
    J Am Pharm Assoc (2003); 2020; 60(1):145-152. PubMed ID: 31791720
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lofexidine: A Newly FDA-Approved, Nonopioid Treatment for Opioid Withdrawal.
    Doughty B; Morgenson D; Brooks T
    Ann Pharmacother; 2019 Jul; 53(7):746-753. PubMed ID: 30724094
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical pharmacokinetics of lofexidine, the alpha 2-adrenergic receptor agonist, in opiate addicts plasma using a highly sensitive liquid chromatography tandem mass spectrometric analysis.
    Yu E; Miotto K; Akerele E; O'Brien CP; Ling W; Kleber H; Fischman MW; Elkashef A; Herman BH; Al-Ghananeem AM
    Am J Drug Alcohol Abuse; 2008; 34(5):611-6. PubMed ID: 18821454
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Phase 3 placebo-controlled, double-blind, multi-site trial of the alpha-2-adrenergic agonist, lofexidine, for opioid withdrawal.
    Yu E; Miotto K; Akerele E; Montgomery A; Elkashef A; Walsh R; Montoya I; Fischman MW; Collins J; McSherry F; Boardman K; Davies DK; O'Brien CP; Ling W; Kleber H; Herman BH
    Drug Alcohol Depend; 2008 Sep; 97(1-2):158-68. PubMed ID: 18508207
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alpha2 adrenergic agonists for the management of opioid withdrawal.
    Gowing L; Farrell M; Ali R; White J
    Cochrane Database Syst Rev; 2004 Oct; (4):CD002024. PubMed ID: 15495025
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alpha2-adrenergic agonists for the management of opioid withdrawal.
    Gowing L; Farrell M; Ali R; White JM
    Cochrane Database Syst Rev; 2009 Apr; (2):CD002024. PubMed ID: 19370574
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of pharmacological treatments for opioid-dependent adolescents: a randomized controlled trial.
    Marsch LA; Bickel WK; Badger GJ; Stothart ME; Quesnel KJ; Stanger C; Brooklyn J
    Arch Gen Psychiatry; 2005 Oct; 62(10):1157-64. PubMed ID: 16203961
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase III, randomized, multi-center, double blind, placebo controlled study of safety and efficacy of lofexidine for relief of symptoms in individuals undergoing inpatient opioid withdrawal.
    Gorodetzky CW; Walsh SL; Martin PR; Saxon AJ; Gullo KL; Biswas K
    Drug Alcohol Depend; 2017 Jul; 176():79-88. PubMed ID: 28527421
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alphaâ‚‚-adrenergic agonists for the management of opioid withdrawal.
    Gowing L; Farrell M; Ali R; White JM
    Cochrane Database Syst Rev; 2016 May; 2016(5):CD002024. PubMed ID: 27140827
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness of low-dose naltrexone in the post-detoxification treatment of opioid dependence.
    Mannelli P; Patkar AA; Peindl K; Murray HW; Wu LT; Hubbard R
    J Clin Psychopharmacol; 2007 Oct; 27(5):468-74. PubMed ID: 17873678
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alpha2 adrenergic agonists for the management of opioid withdrawal.
    Gowing L; Farrell M; Ali R; White J
    Cochrane Database Syst Rev; 2003; (2):CD002024. PubMed ID: 12804419
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alpha2-adrenergic agonists for the management of opioid withdrawal.
    Gowing L; Farrell MF; Ali R; White JM
    Cochrane Database Syst Rev; 2014 Mar; (3):CD002024. PubMed ID: 24683051
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparison of buprenorphine and lofexidine for community opiate detoxification: results from a randomized controlled trial.
    Raistrick D; West D; Finnegan O; Thistlethwaite G; Brearley R; Banbery J
    Addiction; 2005 Dec; 100(12):1860-7. PubMed ID: 16367987
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.